SCHEMBL1574976

SCHEMBL1574976

O=C(Nc1cccc(Cl)c1)N1CC(N(CCO)CCO)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
ALDH1A1 P00352 1/20 0.56
RECQL P46063 1/20 0.56
GRIN2B Q13224 7/20 0.55
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
CCR2 P41597 1/20 0.47
KCNH2 Q12809 1/20 0.47
OPRK1 P41145 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574779 0.89 NPSR1 (0.55) NPSR1MEN1KMT2AALDH1A1RECQL
SCHEMBL1575390 0.87 NPSR1 (0.52) NPSR1MEN1KMT2AALDH1A1RECQL
SCHEMBL1574991 0.86 ALDH1A1 (0.58) NPSR1MEN1KMT2AALDH1A1RECQL
SCHEMBL1574656 0.85 ALDH1A1 (0.56) NPSR1MEN1KMT2AALDH1A1GRIN2B
SCHEMBL1575240 0.85 PAX8 (0.51) MEN1KMT2AALDH1A1NPC1MAPT
SCHEMBL1574671 0.85 ALOX5 (0.54) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL1575584 0.84 GRIN2B (0.51) ALDH1A1GRIN2BNPC1RAB9AMAPT
SCHEMBL1575216 0.83 GRIN2B (0.58) NPSR1MEN1KMT2AGRIN2BRAB9A
SCHEMBL1575588 0.83 NPSR1 (0.54) NPSR1MEN1KMT2AALDH1A1RECQL
SCHEMBL1575079 0.82 MAPT (0.57) MEN1KMT2AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB NPSR1 1387/4885MEN1 1113/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.